<DOC>
	<DOCNO>NCT02503462</DOCNO>
	<brief_summary>The purpose study ass whether boost cobicistat result similar concentration darunavir brain compare boost ritonavir .</brief_summary>
	<brief_title>Effect Cobicistat Versus Ritonavir Boosting Brain Permeation Darunavir HIV-infected Individuals</brief_title>
	<detailed_description>Cobicistat new pharmacokinetic enhancer booster HIV protease inhibitor darunavir . Cobicistat distinct conventional booster ritonavir cobicistat present selective inhibition enzyme metabolize drug . In addition , cobicistat weaker inhibitor efflux drug transporter express level blood-brain barrier ( i.e . P-glycoprotein ( P-gp ) breast cancer resistance Protein ( BCRP ) ) . A weak inhibition efflux transporter could possibly result less darunavir enter brain boost cobicistat compare boost ritonavir . Such difference could potentially critical patient HIV-associated neurocognitive disorder sufficient drug level need efficiently inhibit HIV replication inside brain . The aim study determine whether boost darunavir cobicistat result effectively low darunavir concentration CSF compare boost ritonavir . The study perform HIV infect patient present HIV associate neurocognitive disorder ( HAND ) require lumbar puncture clinical reason . In addition , patient eligible treated qualify darunavir/ritonavir ( 800/100 mg daily ) contain regimen . Darunavir concentration measure simultaneously CSF plasma ( CSF/plasma ratio ) first ritonavir boost subsequently cobicistat boosting .</detailed_description>
	<mesh_term>Dementia</mesh_term>
	<mesh_term>AIDS Dementia Complex</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Darunavir</mesh_term>
	<mesh_term>Cobicistat</mesh_term>
	<criteria>document HIV infection presence HIV associate neurocognitive disorder require lumbar puncture clinical reason treatment qualify treat HIV therapy include darunavir/r ( 800/100 mg daily ) ability comply study requirement inform consent condition disrupt bloodbrain barrier thereby impact entry drug brain ( meningitis , meningoencephalitis , multiple sclerosis , progressive multifocal leucoencephalopathy ) comedications inhibiting/inducing Pglycoprotein BCRP comedications inhibiting/inducing cytochrome P450 isoenzyme 3A4 ( CYP3A4 ) non adherence Treatment pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>HIV</keyword>
	<keyword>darunavir</keyword>
	<keyword>ritonavir</keyword>
	<keyword>cobicistat</keyword>
	<keyword>CSF</keyword>
	<keyword>pharmacokinetics</keyword>
</DOC>